TC
CASC

TFS Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

TFS Capital’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-62,283
Closed -$231K – 551
2017
Q2 		$231K Sell
62,283
-13,501
-18% -$53.6K 0.09% 404
2017
Q1 		$314K Buy
+75,784
New +$319K 0.1% 367
2016
Q4 		– Sell
-3,220
Closed -$32K – 993
2016
Q3 		$32K Buy
+3,220
New +$22.8K 0.01% 720
2016
Q2 		– Sell
-2,231
Closed -$17K – 1328
2016
Q1 		$17K Sell
2,231
-3,356
-60% -$25.8K ﹤0.01% 975
2015
Q4 		$74K Sell
5,587
-8,312
-60% -$143K 0.01% 684
2015
Q3 		$228K Sell
13,899
-10,716
-44% -$220K 0.02% 717
2015
Q2 		$552K Sell
24,615
-59,019
-71% -$934K 0.05% 492
2015
Q1 		$818K Buy
83,634
+69,527
+493% +$682K 0.08% 408
2014
Q4 		$161K Sell
14,107
-37,539
-73% -$407K 0.02% 853
2014
Q3 		$595K Buy
51,646
+12,466
+32% +$190K 0.05% 536
2014
Q2 		$762K Sell
39,180
-20,826
-35% -$367K 0.06% 501
2014
Q1 		$1.08M Buy
60,006
+26,724
+80% +$439K 0.07% 424
2013
Q4 		$351K Buy
33,282
+21,103
+173% +$236K 0.02% 1009
2013
Q3 		$151K Sell
12,179
-31,700
-72% -$334K 0.01% 1320
2013
Q2 		$413K Buy
+43,879
New +$564K 0.02% 982

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

TFS Capital's CASC Position: Q3 2017 in Review

TFS Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2017, closing a stake of 62,283 shares — an estimated $231K sold.

TFS Capital first reported a position in CASC in Q2 2013 and held it in 15 quarters. The position peaked at $1.08M in Q1 2014. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

  • TFS Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 62,283 Cascadian Therapeutics, Inc. shares in Q3 2017, an estimated $231K.
  • TFS Capital first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 15 quarters.
  • TFS Capital's Cascadian Therapeutics, Inc. position peaked at $1.08M in Q1 2014.
  • 79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.